SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma [SUTNET Trial: Studio Clinico-Biologico Di Fase II Con Sunitinib In Pazienti Affetti Da Feocromocitomi/Paragangliomi In Stadio Avanzato e/o Non Resecabile]

Trial Profile

SUTNET Trial: Biological and Clinical Phase II study of Sunitinib in patients with unresectable and/or metastatic pheochromocytoma/paraganglioma [SUTNET Trial: Studio Clinico-Biologico Di Fase II Con Sunitinib In Pazienti Affetti Da Feocromocitomi/Paragangliomi In Stadio Avanzato e/o Non Resecabile]

Recruiting
Phase of Trial: Phase II

Latest Information Update: 10 Oct 2013

At a glance

  • Drugs Sunitinib (Primary)
  • Indications Paraganglioma; Pheochromocytoma
  • Focus Pharmacogenomic; Therapeutic Use
  • Acronyms SUTNET
  • Most Recent Events

    • 10 Oct 2013 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top